More Like this

1. A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China

   https://doi.org/10.1002/cld.1109  

   Adee, Madeline; Zhuo, Yueran; Zhan, Tiannan; Chen, Qiushi; Toumi, Asmae; Ayer, Turgay; Nwankwo, Chizoba; Zhong, Huaiyang; Puenpatom, Amy; Chhatwal, Jagpreet (April 2021, Clinical Liver Disease)
2. FEASIBILITY AND COST OF HEPATITIS C ELIMINATION IN CHINA

   Chhatwal, J; Zhuo, Y; Chen, Q; Zhan, T; Chen, W; Ayer, T; Nwankwo, C; Puenpatom, A (January 2019, Hepatology)
3. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan

   https://doi.org/10.1001/jamanetworkopen.2019.3613  

   Chhatwal, Jagpreet; Chen, Qiushi; Wang, Xiaojie; Ayer, Turgay; Zhuo, Yueran; Janjua, Naveed Z.; Kanwal, Fasiha (May 2019, JAMA Network Open)
4. The impact of direct‐acting anti‐virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States

   https://doi.org/10.1111/apt.15291  

   Chhatwal, Jagpreet; Chen, Qiushi; Bethea, Emily D.; Hur, Chin; Spaulding, Anne C.; Kanwal, Fasiha (May 2019, Alimentary Pharmacology & Therapeutics)

   Summary BackgroundThe hepatitis C virus (HCV) care cascade has changed dramatically following the introduction of direct‐acting anti‐virals (DAAs). Up‐to‐date estimates of the cascade are needed to monitor progress, identify key gaps and inform policy. AimTo estimate the current and future HCV care cascade in the United States, nationally and in select subpopulations of interest. MethodsWe used a previously validated mathematical model to simulate the landscape of HCV in the United States from 2011 onwards, accounting for HCV screening policy updates, newer HCV treatments and rising HCV incidence. ResultsBy the end of 2018, of 4.29 million HCV persons alive, 2.71 million (63%) were actively viremic, 2.24 million (52%) aware and 1.58 million (37%) cured. By 2030, under the status quo, of 3.65 million HCV persons alive, 1.88 million (51%) would be viremic, 2.25 million (62%) aware and 1.77 million (49%) cured. The HCV care cascade in 2018 differed substantially by subpopulation: of 1.34 million incarcerated HCV persons, 96% were viremic, 36% aware and 4% cured; of 0.87 million HCV persons in Medicare, 31% were viremic, 72% aware and 69% cured; and of 0.37 million HCV persons in Medicaid, 49% were viremic, 54% aware and 51% cured. Implementing universal screening, providing unrestricted treatment and controlling HCV incidence were factors found to have the largest effect on improving the HCV care cascade. ConclusionsSince the launch of DAAs, the HCV care cascade has shifted towards higher awareness and treatment rates; however, additional interventions are needed to move towards HCV elimination. 

   more » « less
5. Current and Future Diagnostics for Hepatitis C Virus Infection

   https://doi.org/10.3390/chemosensors13020031  

   Zilouchian, Hussein; Faqah, Omair; Kabir, Md Alamgir; Gross, Dennis; Pan, Rachel; Shaifman, Shane; Younas, Muhammad Awais; Haseeb, Muhammad Abdul; Thomas, Emmanuel; Asghar, Waseem (February 2025, Chemosensors)

   Hepatitis C virus (HCV), a member of the Flaviviridae family, is an RNA virus enclosed in an envelope that infects approximately 50 million people worldwide. Despite its significant burden on public health, no vaccine is currently available, and many individuals remain unaware of their infection due to the often asymptomatic nature of the disease. Early detection of HCV is critical for initiating curative treatments, which can prevent long-term complications such as cirrhosis, liver cancer, and decompensated liver disease. However, conventional diagnostic approaches available, such as enzyme immunoassays (EIAs) and polymerase chain reaction (PCR)-based methods, are often costly, time-intensive, and challenging to be implemented in resource-limited settings. This review provides an overview of HCV disease and the structural components of the virus, illustrating how different diagnostic methods target various parts of the viral structure. It examines current diagnostic tests and assays, highlighting their mechanisms, applications, and limitations, which necessitates the development of improved detection methods. Additionally, the paper explores emerging technologies in HCV detection that could offer affordable, accessible, and easy-to-use diagnostic solutions, particularly for deployment in low-resource and point-of-care settings. These advancements have the potential to contribute significantly to achieving the World Health Organization’s (WHO) target of eliminating HCV as a public threat by 2030. 

   more » « less